Answers are grounded in this paper and cite their sources.
Experimental findings demonstrate FKL-137 inhibits erythroleukemia cell growth, suggesting new treatment avenues.
Erythroleukemia is a rare hematological malignancy in clinical practice, and currently, there are no effective treatment options other than stem cell transplantation. The study found that the fluoroquinoline compound FKL-137 can significantly inhibit the proliferation of erythroleukemia cells and induce apoptosis in vitro, while in vivo, it prevents the development of Friend virus-induced erythroleukemia and splenomegaly in mice. Mechanistic studies revealed that FKL-137 reduces glucose uptake and lactate secretion in erythroleukemia cells by targeting GLUT1 and inhibits the expression of glucose metabolism-related proteins, including PKM2, HK2, and LDH. Additionally, FKL-137 modulates the PI3K/AKT signaling pathway, which is closely associated with GLUT1. These results highlight the critical role of GLUT1 in the growth and survival of erythroleukemia and demonstrate that FKL-137 exerts its regulatory effects on glucose metabolism through the dual-targeting of GLUT1 and the PI3K/AKT signaling pathway, making it a potential therapeutic agent for erythroleukemia.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: